GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Plans » Centene Corp (NYSE:CNC) » Definitions » Cash And Cash Equivalents

Centene (Centene) Cash And Cash Equivalents : $17,193 Mil (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Centene Cash And Cash Equivalents?

Centene's quarterly cash and cash equivalents increased from Jun. 2023 ($17,170.00 Mil) to Sep. 2023 ($18,190.00 Mil) but then stayed the same from Sep. 2023 ($18,190.00 Mil) to Dec. 2023 ($17,193.00 Mil).

Centene's annual cash and cash equivalents declined from Dec. 2021 ($13,118.00 Mil) to Dec. 2022 ($12,074.00 Mil) but then increased from Dec. 2022 ($12,074.00 Mil) to Dec. 2023 ($17,193.00 Mil).


Centene Cash And Cash Equivalents Historical Data

The historical data trend for Centene's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centene Cash And Cash Equivalents Chart

Centene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12,123.00 10,800.00 13,118.00 12,074.00 17,193.00

Centene Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12,074.00 15,853.00 17,170.00 18,190.00 17,193.00

Centene Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Centene  (NYSE:CNC) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Centene Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Centene's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Centene (Centene) Business Description

Address
7700 Forsyth Boulevard, Centene Plaza, St. Louis, MO, USA, 63105
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.
Executives
Lori Jean Robinson director 5875 LANDERBROOK DRIVE, SUITE 220, CLEVELAND OH 44124
Andrew Lynn Asher officer: EVP, CFO 8735 HENDERSON ROAD, TAMPA FL 33634
James E Murray officer: EVP, Chief Transform. Officer 500 WEST MAIN STREET, LOUISVILLE KY 40202
Samuels Theodore R. Ii director 1990 E. GRAND AVE., EL SEGUNDO CA 90245
Monte E Ford director C/O AKAMAI TECHNOLOGIES, INC., 8 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Kenneth J Fasola officer: EVP, Health Care Enterprises 500 WEST MAIN STREET, LOUISVILLE KY 40202
Shannon Bagley officer: EVP, Chief Admin. Officer 7700 FORSYTH BOULEVARD, CLAYTON MO 63105
Richard A Gephardt director 822 CAPITOL SQUARE PLACE, SW, WASHINGTON DC 20024
Christopher J Coughlin director
H James Dallas director 127 PUBLIC SQUARE, CLEVELAND OH 44114
Mark J Brooks officer: SVP, Chief Information Officer 7700 FORSYTH BOULEVARD, ST. LOUIS MO 63105
David P Thomas officer: EVP, MARKETS 7700 FORSYTH BOULEVARD, ST. LOUIS MO 63105
Leslie V Norwalk director C/O 3661 VALLEY CENTRE DRIVE SUITE 200, SAN DIEGO CA 92130
Wayne S Deveydt director 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Toney Colin A officer: EVP, Mergers & Acquisitions 7700 FORSYTH BOULEVARD, ST. LOUIS MO 63105

Centene (Centene) Headlines